Clinical Trial

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-08.
Status change: Not Yet Recruiting → Recruiting 2024-04-19
Trial Details
NCT Number NCT06360042
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Unresectable Hepatocellular Carcinoma
Enrollment 111 participants
Start Date 2024-01-01
Primary Completion 2027-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-22